Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bridge Laboratories has reached an agreement to build its second preclinical facility in China. The 150,000 square foot facility will be adjacent to Bridge's existing laboratory in the Zhongguancun Life Science Park located in Beijing, China.
Subscribe to our email newsletter
According to Bridge Laboratories, construction of the new laboratory will begin in the fourth quarter of 2008. This facility, expected to be completed in late fourth quarter of 2009 and designed to meet the FDA and worldwide regulatory standards, will provide GLP toxicology, immunology, vaccine, and bioanalytical services. The new facility is expected to quadruple Bridge’s available laboratory space in Beijing.
Tom Oakley, president and CEO of Bridge Laboratories, said: “Bridge is committed to providing quality preclinical services to our customers, and this new facility will enable us to expand our ability to deliver US-level regulatory compliant outsourced discovery and development services in a cost-effective manner.”